After a five-year Phase III study, Lilly has decided not to submit arzoxifene to regulatory authorities. The osteoporosis treatment met its primary endpoints in the trial, but failed to demonstrate efficacy against placebo in the secondary endpoints. In addition, some adverse events occurred more frequently than in the placebo. “At Lilly, our goal is to provide innovative therapies that result in better patient outcomes,” said M. Johnston Erwin, global brand development leader for...